Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

NCT07088731 | Not Yet Recruiting Phase 2

• 1 other identifier: 25/275-5221
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

For locally advanced cervical cancer, there are two main treatment options: One is radical chemoradiotherapy (a combination of radiotherapy and chemotherapy aimed at curing the disease). The other is having neoadjuvant treatment first (treatment given before the main surgery to shrink the tumor) followed by radical surgery. So far, there's no clear answer on which of these two options is better. In general, cervical cancer responds well to immunotherapy. But we still don't know for sure if adding immunotherapy to neoadjuvant chemotherapy can improve the treatment effect for locally advanced cervical cancer, or even make it better than radical chemoradiotherapy. This study aims to compare the effects of two approaches: radical chemoradiotherapy versus neoadjuvant chemotherapy plus immunotherapy followed by surgery.

Conditions

Cervical Carcinoma

Keywords

locally advanced; neoadjuvent chemotherapy; neoadjuvent immunotherapy; CCRT

Outcome Measures

Primary Outcomes (1)

• 2-year Progression-Free Survival Rate

  From enrollment to the end of treatment at 2 years

Study Arms (2)

neoadjuvent arm

EXPERIMENTAL

Drug: Sintilimab

CCRT arm

ACTIVE COMPARATOR

Radiation: Concurrent chemo-radiotherapy

Interventions

Sintilimab DRUG

neoadjuvent chemotherapy plus sintilimab for 2 cycles followed by radical surgery

Also known as: Nab-paclitaxel, cisplatin

neoadjuvent arm

Concurrent chemo-radiotherapy RADIATION

EBRT+BT+cisplatin

CCRT arm

Eligibility Criteria

• Age: 18 Years - 70 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged ≥ 18 years and ≤ 70 years;
• Cervical cancer with pathological types being squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
• Staged IB3 or IIA2 according to the FIGO 2018 staging system, as assessed by the investigator;
• ECOG performance status of 0-2, or KPS score ≥ 70;
• Expected survival time of more than 3 months;
• Having at least one measurable lesion in accordance with RECIST 1.1;
• Laboratory test results meeting the following criteria without drug intervention:
• Hemoglobin ≥ 90 g/dl, neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L;
• Creatinine ≤ 1.5 times the upper limit of normal range;
• Total bilirubin, alanine transaminase (ALT), and aspartate transaminase (AST) \< 2 times the upper limit of normal;
• Postmenopausal, or reproductive-aged women who meet all the following conditions: non-lactating, not pregnant, and able to use effective contraceptive measures during the study treatment period;
• Voluntarily participating in this study and signing the informed consent form.

You may not qualify if:

• Participated in other clinical trials within 30 days before receiving the first dose of chemotherapy drugs or during the treatment period.
• Previously received any other anti-tumor treatment for cervical cancer.
• Non-HPV-related cervical cancer.
• Needing to receive other anti-tumor treatments during the study treatment period.
• Patients with known allergies to the active ingredients of the study drugs or their excipients.
• Diagnosed with other malignant tumors in the past 5 years (except those judged to be cured by the investigator).
• Active infections requiring systemic treatment.
• Positive for human immunodeficiency virus (HIV) antibody.
• Positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody.
• Peripheral neuropathy with a grade of ≥ 2 according to the NCI-CTCAE (Version 5.0).
• Concurrent diseases or abnormal test results that interfere with the subject's ability to receive anti-tumor treatment as judged by the investigator, such as the estimated inability of the subject to tolerate at least 2 cycles of neoadjuvant chemotherapy plus surgery or concurrent chemoradiotherapy, etc.
• Participation in this study is deemed not conducive to the maximum benefit of the subject as judged by the investigator.

Sponsors & Collaborators

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences: lead

Study Sites (1)

Department of Gynecological Oncology

Beijing, China

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Interventions

sintilimab; 130-nm albumin-bound paclitaxel; Cisplatin

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds

Central Study Contacts

Guangwen Yuan, doctoral

CONTACT

+86 136 9368 4116; william327@126.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 19, 2025
• First Posted: July 28, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: September 22, 2025

Record last verified: 2025-09

Locations

CN (1)